57046-73-8
57046-73-8 structure
- Name: Paprotrain
- Chemical Name: Paprotrain
- CAS Number: 57046-73-8
- Molecular Formula: C16H11N3
- Molecular Weight: 245.279
- Catalog: Signaling Pathways Cell Cycle/DNA Damage Kinesin
- Create Date: 2016-02-10 08:09:06
- Modify Date: 2024-01-10 13:53:16
-
Paprotrain is a cell-permeable inhibitor of the kinesin MKLP-2, inhibits the ATPase activity of MKLP-2 with an IC50 of 1.35 μM and a Ki of 3.36 μM and shows a moderate inhibition activity on DYRK1A with an IC50 of 5.5 μM.
| Name | Paprotrain |
|---|---|
| Synonyms |
2-indol-3-yl-2-oxoacetyl chloride
Indole-3-Glyoxylyl Chloride Indole-3-glyoxyloyl chloride (2Z)-2-(1H-Indol-3-yl)-3-(3-pyridinyl)acrylonitrile 3-Indoleglyoxylyl chloride 3-indoleglyoxyl chloride 3-indolylglyoxalyl chloride 2-indol-3-yl-3-pyridin-3-yl-acrylonitrile 1H-Indole-3-acetonitrile, α-(3-pyridinylmethylene)-, (αZ)- |
| Description | Paprotrain is a cell-permeable inhibitor of the kinesin MKLP-2, inhibits the ATPase activity of MKLP-2 with an IC50 of 1.35 μM and a Ki of 3.36 μM and shows a moderate inhibition activity on DYRK1A with an IC50 of 5.5 μM. |
|---|---|
| Related Catalog | |
| Target |
MKLP-2:1.35 μM (IC50) |
| In Vitro | Paprotrain has been screened on a panel of CNS kinases. While inactive (IC50 >10 μM) on CDK5 and GSK3, it has shown a moderate activity on DYRK1A (IC50=5.5 μM)[1]. Time-lapse microscopy shows that disrupting MKlp2 expression with paprotrain results in polar body extrusion failure. This could be rescued after rescuing oocytes from paprotrain in fresh medium. Cell cycle analysis shows that most oocytes are arrested at metaphase I or telophase I. However, oocyte spindle structure and chromosome alignment are not disrupted after the inhibition of MKlp2 by paprotrain[2]. Paprotrain-treated porcine oocytes suffer failure of nuclear maturation. The number of oocytes arrested at early MI stage increase in a dose-dependent manner after KIF20A activity inhibition, while the percentage of oocytes that reach ATI and MII stages decrease after treatment[3]. |
| Kinase Assay | Kinase activities for each enzyme are assayed in the presence of 15 μM ATP in a final volume of 30 μL. After 30 min incubation at 30°C, the reaction is stopped by harvesting, using a FilterMate harvester, onto P81 phosphocellulose papers which are washed in 1% phosphoric acid. 20 μL of scintillation fluid are added and the incorporated radioactivity measured in a Packard counter. Blank values are subtracted and activities calculated as pmoles of phosphate incorporated during the 30 min incubation. Controls are performed with appropriate dilutions of DMSO. Kinase activities are expressed in % of maximal activity, i.e. in the absence of inhibitors (Paprotrain). IC50 values are obtained from the dose-response curves[1]. |
| Cell Assay | COCs or denuded oocytes (DOs) are cultured in the presence/absence of Paprotrain in vitro. The control groups are performed with pure DMSO at the same concentration. COCs are denuded of their cumulus cells by gentle pipetting with 0.1% (w/v) hyaluronidase. Oocytes with clearly extruded polar bodies are judged to be matured oocytes. After cultured for 44 h, the polar body extrusion rate of matured oocytes is observed using a microscope. Furthermore, chromosomal alignments and the cell cycle of oocytes treated with inhibitor are examined using laser scan confocal microscopy[3]. |
| References |
[3]. Zhang Y, et al. KIF20A regulates porcine oocyte maturation and early embryo development. |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 470.1±40.0 °C at 760 mmHg |
| Molecular Formula | C16H11N3 |
| Molecular Weight | 245.279 |
| Flash Point | 149.2±12.5 °C |
| Exact Mass | 245.095291 |
| PSA | 52.47000 |
| LogP | 3.17 |
| Vapour Pressure | 0.0±1.2 mmHg at 25°C |
| Index of Refraction | 1.739 |
| Storage condition | 2-8℃ |
|
~68%
57046-73-8 |
| Literature: Tcherniuk, Sergey; Skoufias, Dimitrios A.; Labriere, Christophe; Rath, Oliver; Gueritte, Franaoise; Guillou, Catherine; Kozielski, Frank Angewandte Chemie - International Edition, 2010 , vol. 49, # 44 p. 8228 - 8231 |
